Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
Guía práctica de seguimiento y manejo del paciente con asma grave tratado con biológicos / Practical guide for the follow-up and management of patients with severe asthma treated with biologics
Resumen
Resumen
El manejo del asma grave descontrolada con biológicos es un área de extrema dificultad, dada la escasez de información respecto a los criterios de inicio de los mismos, las variables a evaluar para determinar la eficacia y seguridad de su manejo, los puntos de corte para determinar el momento oportuno para cambiar o agregar otro biológico y el proceso para disminuir o retirar los esteroides. Esta revisión incorpora la información más reciente y realiza una propuesta con base en ella.
Abstract
The management of severe uncontrolled asthma with biologics is an area of extreme difficulty given the scarcity of information regarding their starting criteria, the variables to be evaluated to determine the efficacy and safety of their management, the cut-off points to determine the timing to change or add another biological and the process to decrease or withdraw steroids. This review incorporates the latest information and makes a proposal based on it.
Palabras clave
Texto completo:
PDFReferencias
Bousquet J, Mantzouranis E, Cruz AA, Aït-Khaled N, BaenaCagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010;126:926-38. doi: 10.1016/j. jaci.2010.07.019.
National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007;120(5 Suppl.):S94-138. doi: 10.1016/j. jaci.2007.09.043.
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343- 73. doi: 10.1183/09031936.00202013.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention [Internet]; 2020. Disponible en: www.ginasthma.org.
Global Initiative for Asthma. GINA Difficult-to-treat & severe asthma in adolescents and adult patients, Diagnosis and Managment [Internet]. Fontana: Global Initiative for Asthma; 2019. Disponible en: https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0- wms-1.pdf.
Sociedad Española de Neumología y Cirugía Torácica. GEMA5.0 Guía española para el manejo del asma [Internet]. Madrid: Luzán5; 2020. Disponible en: https://www.semg.es/ images/documentos/GEMA_5.0.pdf.
Asociación Latinoamericana de Tórax. Guía de Práctica Clínica Latinoamericana de Asma Grave. Respirar 2020;12:1-76.
Upham JW, Jurak LM. How do biologicals and other novel therapies effect clinically used biomarkers in severe asthma? Clin Exp Allergy. 2020 ;50(9):994-1006. doi: 10.1111/cea.13694.
Fitzpatrick AM, Moore WC. Severe Asthma Phenotypes - How Should They Guide Evaluation and Treatment? J Allergy Clin Immunol Pract. 2017;5(4):901-08. doi: 10.1016/j. jaip.2017.05.015.
Lim HF, Nair P. Airway Inflammation and Inflammatory Biomarkers. Semin Respir Crit Care Med. 2018;39(1):56-63. doi: 10.1055/s-0037-1606217.
Holgate ST, Djukanović R, Casale T, Bousquet J. Antiimmunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005;35(4):408-16. doi: 10.1111/j.1365-2222.2005.02191.x.
Kroes JA, Zielhuis SW, van Roon EN, Ten-Brinke A. Prediction of response to biological treatment with monoclonal antibodies in severe asthma. Biochem Pharmacol. 2020;179:113978. doi: 10.1016/j.bcp.2020.113978.
Pavord ID, Menzies-Gow A, Buhl R, Chanez P, Dransfield M, Lugogo N, et al. Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1121-32.e7. doi: 10.1016/j.jaip.2020.08.039.
Partida-Gaytán A, Torre-Bouscoulet L, Macías MP, Raimondi A, Pizzichini E. Mepolizumab for the treatment of severe eosinophilic asthma. Rev Alerg Mex. 2020;67 Supl 3:s83-s101.
Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086-96. doi: 10.1016/j. jaci.2013.05.020.
Pelaia C, Calabrese C, Vatrella A, Busceti MT, Garofalo E, Lombardo N, et al. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. Biomed Res Int. 2018;2018:4839230. doi: 10.1155/2018/4839230.
Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344-53.e2. doi: 10.1016/j.jaci.2010.04.004.
Koike M, Nakamura K, Furuya A, Iida A, Anazawa H, Takatsu, et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. Hum Antibodies. 2009;18(1-2):17-27. doi: 10.3233/HAB-2009-0198.
Sakae Y, Satoh T, Yagi H, Yanaka S, Yamaguchi T, Isoda Y, et al. Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa. Sci Rep. 2017;7(1):13780. doi: 10.1038/ s41598-017-13845-8.
Bhalla A, Mukherjee M, Nair P. Airway Eosinophilopoietic and Autoimmune Mechanisms of Eosinophilia in Severe Asthma. Immunol Allergy Clin North Am. 2018;38(4):639-654. doi: 10.1016/j.iac.2018.06.003.
Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115-27. doi: 10.1016/ S0140-6736(16)31324-1.
Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017;376(25):2448-58. doi: 10.1056/NEJMoa1703501.
FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6(1):51-64. doi: 10.1016/S2213-2600(17)30344-2.
Corren J, Du E, Gubbi A, Vanlandingham R, et al. Variability in Blood Eosinophil Counts in Patients with Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2021;9(3):1224-31.e9. doi: 10.1016/j.jaip.2020.10.033.
Thibodeaux Q, Smith MP, Ly K, Beck K, Liao W, Bhutani T. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother. 2019;15(9):2129-39. doi: 10.1080/21645515.2019.1582403.
Upham JW, Le Lievre C, Jackson DJ, Masoli M, Wechsler ME, Price DB, et al. Defining a severe asthma super-responder: findings from a Delphi process. BMC Med Res Methodol. 2016;16:56. doi: 10.1183/13993003.congress-2020.2610.
Papaioannou AI, Fouka E, Papakosta D, Papiris S, Loukides S. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best. Clin Exp Allergy. 2021;51(2):221-27. doi: 10.1111/cea.13809.
Johnson N, Varughese B, De La Torre MA, Surani SR, Udeani G. A Review of Respiratory Biologic Agents in Severe Asthma. Cureus. 2019;11(9):e5690. doi: 10.7759/cureus.5690.
Han D, Lee JK. Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab. Ann Allergy Asthma Immunol. 2018;121(6):742-743. doi: 10.1016/j.anai.2018.07.030.
Dedaj R, Unsel L. Case study: A Combination of Mepolizumab and Omaluzimab injections for severe asthma. J Asthma. 2019;56(5):473-74. doi: 10.1080/02770903.2018.1471706.
Ortega G, Tongchinsub P, Carr T. Combination biologic therapy for severe persistent asthma. Ann Allergy Asthma Immunol. 2019;123(3):309-11. doi: 10.1016/j.anai.2019.06.013
Domingo C, Pomares X, Morón A, Sogo A. Dual Monoclonal Antibody Therapy for a Severe Asthma Patient. Front Pharmacol. 2020;11:587621. doi: 10.3389/fphar.2020.587621.
Enlaces refback
- No hay ningún enlace refback.